Stockscreener 앱 받기
20.52
12.68%
-2.98
Ultragenyx Pharmaceutical Inc 주식(RARE)의 최신 뉴스
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A - Insider Monkey
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to - pharmiweb.com
Biopharma bites: Layoffs at Ultragenyx, Gilead's licensing deal, plus a pair of PIPEs and a 340B update - FirstWord Pharma
Ultragenyx Pharmaceutical Class Action Update - Intellectia AI
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire
Ultragenyx Earnings Call Balances Growth With Risk - TipRanks
Ultragenyx (RARE) Faces Revenue Shortfall and Workforce Reductio - GuruFocus
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
Ultragenyx falls as guidance trails consensus (RARE:NASDAQ) - Seeking Alpha
Ultragenyx cuts jobs as it seeks path to profit in 2027 - BioPharma Dive
Why Is Ultragenyx Stock Sinking Friday?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Asianet Newsable
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down on Disappointing Earnings - MarketBeat
Ultragenyx to cut 130 jobs following failed rare-disease drug trial - The Business Journals
Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Truist Cuts Price Target on Ultragenyx Pharmaceutical to $76 From $90, Keeps Buy Rating - marketscreener.com
Ultragenyx (RARE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans - Fierce Biotech
Ultragenyx Pharmaceutical Q4 2025 Earnings Call Transcript - MarketBeat
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Ultragenyx Q4 2025 sees revenue growth, stock dips - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire
Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Estimates By $0.09 EPS - MarketBeat
Earnings Flash (RARE) Ultragenyx Pharmaceutical Posts Q4 EPS -$1.29, vs. FactSet Est of -$1.09 - marketscreener.com
Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Ultragenyx (RARE) Revenue Forecasts Highlight Crysvita and Dojolvi Growth - GuruFocus
Ultragenyx Pharmaceutical Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts - marketscreener.com
Ultragenyx shares fall as 2026 revenue guidance misses expectations - Investing.com
Ultragenyx shares fall as 2026 revenue guidance misses expectations By Investing.com - Investing.com India
Ultragenyx Pharmaceutical Inc. Sued for Securities Law - GlobeNewswire
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update - Bitget
Ultragenyx (RARE) Q4 Revenue Surpasses Expectations, Prepares fo - GuruFocus
Ultragenyx Pharma Loss Narrows; To Cut 10% Of Workforce - Nasdaq
Ultragenyx: Q4 Earnings Snapshot - wwltv.com
Ultragenyx Launches Restructuring Plan to Cut Costs - TipRanks
Ultragenyx: Fourth Quarter Financial Overview - Bitget
Ultragenyx Pharmaceutical Q4 Earnings Report: What Investors Need to Know - Benzinga
Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsRARE - PR Newswire
RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE) - The Malaysian Reserve
Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire
Ultragenyx earnings in focus as gene therapy hopes offset drug flop - Investing.com Nigeria
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
Class Action Lawsuit Filed Against Ultragenyx Pharmaceutical - Intellectia AI
Class Action Announcement for Ultragenyx Pharmaceutical - GlobeNewswire
Earnings Outlook For Ultragenyx Pharmaceutical - Benzinga
Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law - GlobeNewswire
RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve
Levi & Korsinsky Notifies Shareholders of Ultragenyx Pharmaceutical Inc.(RARE) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
What’s the outlook for Ultragenyx Pharmaceutical Inc.’s sectorQuarterly Trade Summary & Stepwise Entry/Exit Trade Alerts - mfd.ru
Ultragenyx Pharmaceutical Inc. (RARE): Investor Outlook Reveals a Promising 168% Potential Upside - DirectorsTalk Interviews
1.12%
0.87%
자본화:
|
볼륨(24시간):